Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Fuehrlein

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Current Neuropharmacology|January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use DisorderAlireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Journal of Addiction Psychiatry|December 5, 2024
Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration TherapyFoojan Zeine, Nicole Jafari, David Baron, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Current Neuropharmacology|January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use DisorderAlireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Journal of Addiction Psychiatry|December 5, 2024
Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration TherapyFoojan Zeine, Nicole Jafari, David Baron, et al.
Pageof 4